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ABSTRACT 
 
Unraveling the Phenotype of Colicin Cytoplasmic Import (cim) Mutants.         
(December 2008) 
Tysheena Perkins Charles, B.S., Xavier University of Louisiana 
Chair of Advisory Committee: Dr. Michael Benedik 
 
Colicins are a type of bacterial toxin produced by Escherichia coli to kill E. coli 
and closely related bacteria. In contrast to the protein secretion pathway, colicins are 
released into the extracellular environment due to lysis of the cell. The colicins then 
enter the target bacterial cell by binding to a surface receptor (ex. BtuB) and 
translocating through an outer membrane channel (ex. OmpF) which is facilitated by the 
interaction with the Tol proteins. Once inside the target cell, pore-forming colicins form 
membrane channels in the inner membrane whereas enzymatic colicins enter the 
cytoplasm to degrade the DNA or RNA. The mechanism used by enzymatic colicins to 
enter the cytoplasm is still unknown and is the focus of my project.  
Cim (cytoplasmic import) mutants were previously discovered in the Benedik 
lab. These mutants are resistant to enzymatic colicins (E2 and E3) but sensitive to pore 
forming colicins (A and E1). It was determined that this phenotype was due to a single 
nucleotide substitution resulting in an amino acid change in tolB.   
The focus of my project was to understand the phenotype of the cim mutants so 
that I could gain more insight regarding the import of enzymatic colicins. To do this I 
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constructed colicin hybrids by swapping the T-R domains with the A-I domains of 
colicins A, E1, and E2. With these hybrids I was able to test whether an enzymatic 
colicin that was coupled with a pore-forming colicin would be functional or not. The 
lack of activity in these hybrids may be due to a lack of essential recognition elements 
used by enzymatic colicins and not possessed by pore-forming colicins.  
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1. INTRODUCTION 
 
1.1 Bacteriocins 
Bacteriocins are proteinaceous toxins produced by bacteria to inhibit the growth 
of similar strains and were first discovered by Gratia in 1925. The colicins of 
Escherichia coli are the most studied bacteriocins, but numerous other types of bacteria 
produce similar toxins to kill neighboring cells. Bacteriocins that are similar to the 
structure of colicins include pyocins, cloacins, pesticins, klebocins, marcescins, 
lumicins, and megacins, however there are numerous others. 
1.2 Colicin Structure 
 Colicin proteins are separated into two groups based on the machinery used by 
the colicins to enter the cell. Group A colicins are translocated into the cell using the Tol 
system whereas Group B colicins use the Ton B system. Colicin genes are generally 
located on a pCol plasmid. The colicin plasmids themselves are also separated into two 
classes, type I and type II. Type I colicin plasmids are small, about 6-10 kb multicopy 
plasmids and type II colicin plasmids are about 40 kb monocopy plasmids that can carry 
either one or two adjacent colicin operons. Group A colicins typically are encoded by the 
smaller type I plasmids, while group B colicins are generally found on the larger type II 
plasmids. 
 Colicins are composed of three domains, the central domain (R) which is  
____________ 
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involved in receptor binding to the outer membrane of the target cell; the N-terminal 
domain (T) which interacts with Tol and is required for translocation across the cell; and 
the C-terminal domain which carries the lethal activity (A). Further downstream in the 
operon is the immunity gene which confers immunity to the strain that is producing the 
colicin (Fig. 1). Colicins are separated into subclasses based on their outer cell 
membrane receptor (6). An example of this are the E colicins which recognize the 
vitamin B12 receptor to gain entry into the cell. 
 
 
   
 
 
1.3 Colicin Expression 
 Colicin transcription is repressed by the LexA protein, the repressor of the SOS 
regulon. There are two overlapping LexA boxes at the colicin promoter (11). When each 
LexA dimer binds to the box, it encourages DNA bending and stops transcription of the 
colicin gene (25). If DNA damage occurs, RecA is activated which causes LexA to 
Figure 1. Schematic Represention of the Colicin Operon. The restriction sites 
indicate the positions used to form the hybrids (discussed in Construction of Hybrids) 
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autocleave. This allows the colicin operon to be transcribed. In the laboratory the 
antibiotic mitomycin C is often used to stimulate the production of the colicin protein. 
1.4 Release of Group A Colicins 
The lysis protein is involved in the release of colicin proteins into the culture 
medium, its gene is generally found downstream of the immunity gene. Transcription of 
the lysis gene relies on read-through from the structural gene promoter across the entire 
operon, which means the lysis protein is coexpressed with colicin. Due to a transcription 
terminator between the colicin and the lysis genes, transcription through the lysis gene is 
much reduced relative to the colicin gene (Fig. 2) (11, 23, 24, 31). The lysis protein is a 
lipoprotein and when in its mature form is found in the outer membrane. 
 
 
 
Figure 2. Transcription of the col Operon. SA, initiation site for transcription of the 
colicin gene; SI, initiation site for transcription of the immunity gene; T1A, first 
termination site for the colicin gene; T2A, second termination site for the colicin 
operon; TI, termination site for the immunity gene. 
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Two models have been proposed for the release of colicins by the lysis protein. 
In both models the lysis protein does not cause true lysis. The first model suggests that 
the lysis protein provokes quasilysis: modifications of the structure of the cell envelope, 
activation of the outer membrane phospholipase A (OmpLA), and death of the producing 
cell. OmpLA is a conserved enzyme that contributes to the virulence of Gram-negative 
bacteria. The phospholipase activity of this enzyme allows the formation of 
lysophospholipids, which as a result permeabilizes the outer and inner membranes of the 
bacterial cell. Because death of the host cell occurs whether or not colicin is expressed, 
the activation of OmpLA is thought to be the cause of this cell death event (29). 
The second model is based on studies with colicin A. These authors tested the 
role of colicins Au (colicin A interacting with porins in the outer membrane) and their 
interaction with the lysis protein to cause secretion of the colicin (9). This model 
addresses a shortcoming of the previous model which did not address if the cells that 
were lysed during release of colicins were the induced or uninduced cells. Colicins Au 
were thought to play a role in the secretion of colicin but were disregarded because 
colicins without porins, which therefore lack colicins Au, still secreted colicin A. Cavard 
studied this hypothesis further by sampling cell extracts for released and unreleased 
colicin A at different time points and from strains that had a mutated lysis protein. From 
this research he was able to propose that membrane proteins, colicin A and the lysis 
protein may form a complex that enables the colicin to be secreted similar to the protein 
secretion process of Gram negative bacteria. 
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1.5 Binding of Colicins to Their Receptor 
Group A and B colicins interact with specific outer membrane proteins of the target. 
Group A, colicins A and E1 to E9, target the vitamin B12 transporter BtuB. There is a 
second outer membrane protein, OmpF or TolC that is needed for translocation which 
suggests that the initial binding is for positioning and the secondary binding is required 
for translocation (7). The BtuB receptor, used by colicins, is an outer membrane pore. It 
contains a “plug” that stops the passage of molecules when energy is not supplied by the 
TonB system. Structural studies show that when the receptor domain of colicin E2 binds 
to BtuB the “plug” still remains (32). This study confirmed that BtuB is only used by 
Group A colicins as a receptor and not a translocon. Although two receptors are 
required, there are certain conditions where the initial binding can be avoided. For 
example with pore-forming colicins, death can still occur when BtuB is bypassed by 
incubating the cells in buffers of low osmotic strength (10).  
Colicins have the same specificity for the receptor as the natural ligand. In a 
competition assay it was seen that colicins compete with the corresponding natural 
ligand for receptor binding, which indicates that there is overlap between the binding site 
of the colicin and the natural ligand. It has also been observed that there is competition 
between colicins and metal chelates. For example, cobalamin can rescue colicin (A or 
E)-treated bacteria, suggesting that this metal chelate displaces a bound colicin from 
BtuB (8), while ferric enterobactin does not displace colicin B, a group B colicin, on 
cells (27). Although these results show an overlap between the binding sites, it does not 
indicate the precise residues involved in binding colicins versus metal chelates. 
 6 
1.6 Translocation in Tol Dependent Colicins 
 The Tol system of E. coli is found in the cell envelope and is composed of five 
proteins. All the functions of these proteins are not known but their regulation is linked 
to cellular stability. Clavel showed that RcsC , which is a sensor that regulates genes 
encoding a major component of the capsula, induces the tol-pal genes in response to 
stress on the cellular envelope (12). In addition to their role in membrane integrity, the 
Tol proteins are also involved in the uptake of bacteriophages and group A colicins. 
Group A colicins require two cell surface receptors for entry into the target cell: 
the cell surface receptor, which does not participate in translocation, and either OmpF or 
TolC, which is used for cell penetration (Figure 3). It has been hypothesized that the N-
terminal domain triggers a process whereby the C-terminal domain is able to cross the 
periplasm and reach the inner membrane or the cytosolic compartment (Figure 3). 
Although the mechanism of this step in transport is unknown, it has been shown that the 
N-terminal domain network interacts with components of the cell envelope.  
 Group A colicins differ in the subsets of Tol proteins used for translocation 
(Table 1). Guihard et al. noticed that the number of colicin A channels increased when 
Tol proteins were overexpressed. This suggests that Tol proteins are recruited as a result 
of colicin binding or OM translocation (17). It was also observed that the number of 
translocation sites per cell correlated with the number of TolA molecules. 
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Colicin Receptor Import Factors Cytotoxicity 
A BtuB OmpF, TolABQR Pore 
E1 BtuB TolC, TolAQ Pore 
E2-E7-E8-E9 BtuB OmpF, TolABQR DNase 
E3-E4-E6 BtuB OmpF, TolABQR 16S RNase 
E5 BtuB OmpF, TolABQR tRNA-specific 
RNase 
K Tsx OmpF, OmpA, 
TolABQR 
Pore 
N OmpF OmpF, TolAQR Pore 
U OmpA OmpF, TolABQR Pore 
Cloacin DF13 LutA OmpF, TolAQR 16S RNase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Receptor, Import Machinery, and Cytotoxic Activity of Group A Colicins. 
Group A colicins, their outer membrane receptor, the machinery used for import, 
and their cytotoxic activity  
 8 
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1.7 Translocation in TonB Dependent Colicins 
 Like Tol, the TonB system in E. coli serves to energize active transport across 
the outer membrane of the cell. This system is parasitized by Group B colicins to gain 
entry into the cell. The TonB system consists of proteins that are functionally similar to 
the Tol system, these proteins include an outer membrane transporter and three inner 
membrane proteins, TonB, ExbB, and ExbD.  
 Unlike group A colicins, group B colicins are able to bind to and translocate 
through their receptor. This is mediated by the presence of a TonB box in the R-domain 
of the colicin. Binding of the R-domain of the colicin to the receptor of the target cell 
causes an interaction between the TonB box of the receptor and TonB itself, causing the 
channel to become “unplugged”. During import of group B colicins, the R-domain of the 
colicin binds the TonB-dependent gated channel. The R-domain then recruits the TonB 
machinery which causes energy input by the ExbBD-TonB complex. Next, the T-domain 
crosses the outer membrane and interacts with TonB. The N-terminal domain dissociates 
from TonB and interacts with ExbB and/or ExbD which causes the activity domain to 
reach the final compartment (Fig. 4) (7). Past experiments have shown that a mutation in 
either exbB or exbD does not confer complete tolerance to colicin presumably because 
TonB can interact with the proteins in the Tol system which substitute (5). Mutations in 
both exbB/D and tolQ/R systems confer complete tolerance (4). While the Tol system 
can substitute for the Ton system in the import of Group B colicins, the reverse is not 
true, Group A colicins can utilize only the Tol system. 
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1.8 Pore-forming Colicins 
Pore-forming colicins contain 10 tightly packed  helices (two are hydrophobic 
and the other eight are hydrophilic). The hydrophobic region of the colicin remains 
tucked inside the hydrophilic helices so that it can be water-soluble. The free colicin then 
binds to the receptor on the susceptible cell (19). The colicin is translocated across the 
outer membrane and rearranges upon interaction with the inner membrane to become a 
membrane-bound protein and form ion channels (Fig. 5) (22). This formation resembles 
an umbrella-like structure by inserting the hydrophobic regions into the membrane while 
the hydrophilic regions lay on the surface (Fig. 5).   
The immunity protein recognizes the C-terminal or A domain of colicins (1, 26). 
The immunity proteins of pore-forming colicins are 11-18 kDa (15, 16, 22) and are 
encoded by the same plasmid as colicin. The immunity protein grants the cell protection 
against the produced colicin but not against colicins of other types, even those with 
similar modes of action (7). They are constitutively expressed at low levels (23). They 
reside in the inner membrane (15, 16) and fall into two classes, which are grouped based 
on the length of their hydrophobic segment: A type and E1 type (7). Colicins A, B, N, 
and U are A type, while colicins E1, 5, K, Ia, and Ib are E1 type.  
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1.9 Enzymatic Colicins 
 Enzymatic colicins enter the cell using either the Tol or TonB systems and then 
further translocate across the inner membrane, but it is not known how this is 
accomplished. The cytotoxic domains of the enzymatic colicins differ from the pore-
forming colicins in that the domain presumably must cross the cytoplasmic membrane in 
order to be active in the cytoplasm. This was studied using colicin B, a pore-forming 
colicin, and colicin D, an enzymatic colicin, where it was seen that enzymatic colicins 
use LepB, a protein of the general secretory pathway that cleaves the leader sequence 
from the amino terminus of membrane and secreted proteins (18). lepB mutant strains 
were killed by colicin B, but not by the enzymatic colicins. Sequence comparisons 
Figure 5. Representation of the Umbrella membrane-bound conformation (21) 
Adopted by Colicin E1. Figure taken from Cascales et al. (7). 
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identified a conserved amino acid sequence in the enzymatic colicins, not found in pore-
forming colicins, upstream of the LepB recognition site (Fig. 6).  
Unlike pore-forming colicins, the immunity proteins of the enzymatic colicins 
are released with the protein bound to the activity domain. This is to prevent colicin 
action on the producing organism before the toxin is released into the environment (Fig. 
6). These proteins are approximately 10 kDa (7). Immunity proteins provide immunity 
either by binding directly to the active site, or by blocking access to the substrate binding 
site (7). It is still unknown how the immunity protein is lost during translocation but it 
has been speculated that it must be released before LepB is able to cleave the catalytic 
domain (13). If the immunity protein is not removed, LepB is not able to cleave the 
colicin.  
The DNase colicins are one subset of the enzymatic colicins, they cleave or 
degrade DNA in a non-site specific manner. The DNase colicins share about 65% 
sequence identity and include colicins E2, E7, E8, and E9. There is an H-N-H motif in 
the DNase colicins that is the core of the active site (7), the N-terminal histidine residue 
serves as a general base in the hydrolysis mechanism. The asparagine residue forms a 
stabilizing hydrogen bond backbone across the motif and C-terminal histidine is a metal 
binding residue. This enzyme most likely causes double-stranded breaks in the DNA and 
also poorly cleaves single-stranded RNA.  
 RNase colicins include colicins E3, E4, E5, E6, and D. These colicins cause cell 
death by inhibiting protein synthesis through a specific phosphodiester bond cleavage in 
RNA. These enzymes are separated into two groups: rRNases, which attack the 30S 
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subunit of the bacterial ribosome, (colicins E3, E4, and E6) (2, 3, 30), and tRNases, 
which cleave single phosphodiester bonds in the anticodon loops of specific transfer 
RNAs (colicins E5 and D) (7).  
 
  
 
 
 
1.10 Cytoplasmic Import (cim) Mutants 
 A variety of E. coli mutants have been isolated which confer resistance, or 
tolerance, to colicins. These “tolerant” mutants were how the tol genes were identified. 
Figure 6. Schematic Drawing of the Colicin B and D Killing Pathways. Dark blue, long 
coiled-coil receptor; medium green, FepA receptor; light blue, translocation domain; 
light green, TonB protein; patterned light green, ExbB and D; yellow, immunity 
protein; dark green, LepB; red, catalytic domain.  The receptor interacts with the R 
domain of both colicins. The T domain the interacts with TonB, ExbB and D. On 
colicin D, the immunity protein comes off and then LepB cuts upstream the catalytic 
domain. For colicin B the immunity protein is not bound and it forms channels in the 
inner membrane. Figure taken from Jakes (18) 
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Null mutants within any of the tol genes generally confer tolerance to all members of 
Group A colicins. 
 In order to identify genes specific to the cytoplasmic import step of enzymatic 
colicin translocation, a mutant hunt was initiated in our lab. This was done by screening 
colonies that were resistant to E2 but remained sensitive to E1, to ensure that there was 
not a mutation in the BtuB receptor or the other common elements. These mutants, 
which were resistant to the cytoplasmic colicins (E2 and E3) but sensitive to pore-
forming colicins (A and E1), were called cytoplasmic import (cim) mutants. Mutants 
were then mapped and sequenced to discover the locus of the Cim phenotype. Sequence 
analysis revealed that each mutant carried a singe nucleotide change which led to an 
amino acid change in TolB (unpublished). Of the thirteen mutants sequenced three 
different substitutions were found (Table 2). The mutant alleles were then cloned and 
transformed into a tolB deleted strain. Performing a colicin spot test demonstrated that 
the mutations in tolB were sufficient to cause the Cim phenotype. This is interesting 
because although colicins A, E2, and E3 all require TolB, the cim mutants are only 
resistant to colicins E2 and E3. This leads us to believe that there must be a difference, 
involving TolB, in the specificity of the uptake between pore-forming colicins and 
enzymatic colicins. Overexpression of the cim alleles does not compensate for the 
defect, which means that the phenotype was not caused by an insufficient amount of 
TolB (unpublished). 
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Strain Resistance 
Phenotype 
Sequence Change Residue Change 
MB1708 Col:ASE1SE2RE3R TCT  TAT Ser406  Tyr 
MB1760 Col:ASE1SE2RE3R TCC  TAC Ser225  Tyr 
MB2656 Col:ASE1SE2RE3R TTC  TCC Phe424  Ser 
 
 
1.11 Summary of Aims 
 Colicins A, E1, and E2 require TolABQR, whereas colicin E1 requires TolACQ. 
The differences in the requirements for import causes one to question if there is any 
specificity in the uptake between pore-forming and enzymatic colicins and the usage of 
Tol proteins.   
 Although much is known about colicins, there is still very little understood about 
how colicins translocate across the inner membrane to reach the target where their lethal 
activity takes place. The phenotype of the cim mutants showed that there was a 
difference in how pore-forming and enzymatic colicins used the Tol proteins. My project 
was designed to probe this by better understanding the cim mutants. Characterizing the 
phenotype of the cim mutants would help determine if the tolB allelles blocked an import 
step used by enzymatic but not pore-forming colicins or if the translocation domain itself 
was not recognized due to the differences in import machinery needed between the 
colicins. To understand this I attempted to: 
a. Build hybrids by swapping the domains of the colicins 
Table 2. Sequences of the cim Mutants. 
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b. Compare the hybrids to wild-type strains vs. strains with the Cim defect. 
The hybrids were designed to see if the translocation machinery could be changed 
between colicins or if some type of recognition occurs between the T-R domains and the 
activity domain. If the results indicated that the phenotype was specific to the activity 
domain, future experiments would be done to try to understand the role of TolB in the 
transit across the inner membrane of colicins E2 and E3.  
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2. MATERIALS AND METHODS 
 
2.1 Bacterial Strains and Plasmids 
The bacterial strains and plasmids used throughout this work are described in 
Table 3. 
 
 
Strain/Plasmid Relevant Characteristics Reference 
Plasmids 
pBC SK+ CamR cloning vector Stratagene 
pC2G pMALC2G with a deletion of the Maltose Binding 
Protein domain 
Lab stock 
Strains 
MB1674 W3110 ColE1 Lab stock 
MB1801 ColA-CA31 Lab stock 
MB1920 W3110 ColE2-P9 Lab stock 
MB3436 MM294 but lacIq lacZ M15 Lab stock 
MB3636 pC2G Lab Stock 
MB3789 TRE2 into pC2G BamHI XbaI (a.a. 1-448) This work 
MB3791 AIE2 into pBC XbaI HindIII (a.a. 449-581) This work 
MB3811 AIE2 cloned into 3789 This work 
MB3853 TRE1 into pC2G BamHI XbaI (a.a. 1-378) This work 
MB3856 TRA into pC2G BamHI XbaI (a.a. 1-393) This work 
MB3858 AIA into pBC XbaI HindIII (a.a. 394-592) This work 
MB3872 AIE1 into pBC XbaI HindIII (a.a. 379-522) This work 
MB4018 TRAIE1 into pC2G BamHI HindIII (a.a. 1-522) This work 
MB4020 TRAIE2 into pC2G BamHI HindIII (a.a. 1-581) This work 
MB4031 p4018 with XbaI insertion between a.a. 345 and 346 
(XbaI-1) 
This work 
MB4032 p4018 with XbaI insertion between a.a. 356 and 357 
(XbaI-2) 
This work 
MB4033 TRAIA in pC2G BamHI and HindIII (a.a. 1-592) This work 
MB4039 p4033 with XbaI insertion between a.a. 424 and 425  This work 
MB4040 AIA into pBC XbaI and HindIII This work 
MB4042 AIE1 (4031) into pBC XbaI and HindIII This work 
MB4044 AIE1 (4032) into pBC XbaI and HindIII This work 
MB4047 AIE2 cloned into 4031 This work 
MB4049 AIE1 (4032) cloned into 4031 This work 
MB4051 AIA cloned into 4031 This work 
MB4053 AIE2 cloned into 4032 This work 
Table 3. Strains and Plasmids.  
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MB4055 AIE1 (4031) cloned into 4032 This work 
MB4057 AIA cloned into 4032 This work 
MB4059 AIE1 (4031) cloned into 3789 This work 
MB4061 AIE1 (4032) cloned into 3789 This work 
MB4063 AIA cloned into 3789 This work 
MB4065 AIE1 (4031) cloned into 4039 This work 
MB4067 AIE1 (4032) cloned into 4039 This work 
MB4069 AIE2 cloned into 4039 This work 
 
 
2.2 Culture Media 
All strains were grown either in LB 505 broth, autoinduction media of Studier, 
which is LB broth containing 0.05% glucose, 0.5% glycerol (0.2% lactose added when 
necessary to induce protein expression) or Terrific Broth unless otherwise mentioned 
(33). Antibiotics were used at concentrations of 100 µg/mL ampicillin or 30 µg/mL 
chloramphenicol for selection of plasmids. 
2.3 Preparation of Chemical Competent and Electrocompetent Cells 
 An overnight culture of MB3436 grown in LB 505 was diluted 1000-fold in 200 
mL of LB and grown at 37ºC to a density of OD600 0.2. The cells were chilled on ice for 
1 hour and harvested by centrifugation for 10 minutes at 4ºC in 50 mL conical tubes. 
The cells were then resuspended in transformation and storage buffer (1/10 original 
volume), aliquoted on dry ice, and stored at -80ºC. 
 The growth conditions for electrocompetent cells were the same as the chemical 
competent cells. After the cells were harvested by centrifugation they were resuspended 
in half the original volume of 10% cold glycerol and centrifuged for 15 minutes at 4ºC. 
Table 3. (continued) 
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The second wash was with 2/5 the volume and the cells were finally resuspended in 1 
mL 10 % glycerol, aliquoted, and stored at -80ºC.  
2.4 Transformation and Electroporation 
Transformations were done by thawing competent cells on ice and adding 50µL 
of the cells to a chilled microcentrifuge tube with 2µL plasmid DNA and incubated on 
ice for 15 minutes. The tubes were then heat shocked at 43ºC for 45 seconds and 
returned to ice for 2 minutes, then 500µL of LB was then added to the tube and 
incubated for 1 hour at 37ºC with agitation. After incubation, 100µL was spread on 
selective plates and grown overnight.  
Electroporations were done when more transformants were needed. 
Electrocompetent cells were thawed on ice and 50µL were added to a chilled eppendorf 
tube with 2µL plasmid DNA and kept on ice for 15 minutes. This mixture was then 
electroporated with an electrical pulse of 1.80 kV. 500µL of LB was then added to the 
tube and incubated for 1 hour at 37ºC with agitation. After incubation, 100µL was 
spread on selective plates and grown overnight. 
2.5 Plasmid Miniprep 
Cultures were grown overnight in LB 505 supplemented with the appropriate 
antibiotic and plasmid DNA was obtained using the boiling miniprep method. The 
overnight culture (1.5 mL) was placed in a microcentrifuge tube, centrifuged, and 
resuspended in 0.5 mL STET (8% sucrose, 5% Triton X-100, 50 mM Tris pH 8) with 25 
µL lysozyme (10 mg/mL). The tubes were then vortexed to resuspend the cells, and 
placed at 100ºC for 3 minutes followed by centrifugation for 20 minutes at full speed. 
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The pellet was removed and 0.5 mL of isopropanol was added to the supernatant to 
precipitate the DNA. The tube was again vortexed and centrifuged for 5 minutes 
following a rinse with 70% EtOH. The EtOH was then removed using a vacuum and 
once the pellet dried, it was resuspended in 100 µL TE (10 mM Tris-HCl pH 8, 1mM 
EDTA). For use in site-directed mutagenesis the QIAprep Spin Miniprep protocol was 
used in order to obtain highly purified DNA.  
2.6 Expression of Protein 
 To express colicin from wild type colicin plasmid carrying cells, 2 mL cultures 
were grown overnight in LB 505 then diluted 1:100 in 10 mL of LB 505 and grown at 
37ºC with agitation until mid-log phase. Mitomycin C (0.2 µg/mL) was added to the 
cultures and incubated for an additional 3 hours. The cells were removed by centrifuging 
the cultures at top speed for 10 minutes at 4ºC and the culture supernatant containing 
colicin stored at -20ºC. 
  Colicin expression from pC2G clones was done similarly but in Terrific Broth 
with ampicillin. IPTG ( 0.1M) was added for induction instead of mitomycin C. To 
harvest the protein, 1.5 mL of culture was placed in a microcentrifuge tube on ice and 
sonicated (10 cycles of 30 seconds sonication with 10 seconds of cooling in between). 
The tubes were then centrifuged at room temperature for 2 minutes to pellet debris, 
placed on ice, and aliquots of the supernatant were made and stored at -20ºC.    
2.7 PCR Amplification, Site Directed Mutagenesis and Cloning  
PCR amplification was used in the construction of the hybrids (Figure 1). The   
T-R (translocation and receptor) domains were amplified with the restriction sites 
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BamHI upstream of the gene and XbaI at the fusion junction (Table 4). The A-I (activity 
and immunity) domains were amplified with the restriction sites XbaI at the fusion 
junction and HindIII downstream of the immunity gene (Table 4). The PCR-amplified T-
R and A-I domains were digested with the appropriate enzymes and cloned into the 
pC2G and pBC vectors, respectively. The resulting recombinant plasmids were then 
transformed into MB3436.  
A second approach used was to amplify the entire colicin and immunity operon. 
The primers incorporated a BamHI restriction site upstream of the colicin operon and a 
HindIII restriction site downstream of the immunity gene (Table 4). The PCR product 
was cloned into the pC2G vector digesting both the plasmid and the vector with BamHI 
and HindIII. The resultant plasmid was subjected to site directed mutagenesis to insert 
an XbaI restriction site at the end of the receptor domain and beginning of the activity 
domain, the fusion junction (Table 4). Mutagenesis was done using the QuikChange® 
Site-Directed Mutatgenesis Kit (Stratagene, La Jolla, CA). The DNA was digested with 
DpnI followed by electroporation into MB3436 electrocompetent cells. 
2.8 Construction of Hybrids 
To combine the two domains a digestion was set up using XbaI and HindIII for 
each T-R and A-I containing plasmid. The fragments were purified, ligated together and 
transformed into MB3436. The transformation was plated on LB plates containing 
ampicillin plus the colicin appropriate for the A-I domain in order to select for it. 
Colonies were screened using a triple digestion, BamHI, HindIII, and XbaI. Following 
this, the immunity region of the A-I colicins was tested by performing a spot test. Strains 
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carrying the appropriate plasmids were stored at -80°C for future use, after confirmation 
by DNA sequencing. 
2.9 Sensitivity Testing 
 Resistance and sensitivity of strains were tested on lawns prepared with 
overnight cultures, 0.1 mL of the overnight culture was added to 3 mL top agar and 
poured onto an LB agar plate. Once solidified, 5 µL of each sample was spotted on the 
plate and incubated at 37ºC overnight. The results were recorded and compared to a 
control strain. 
2.10 Competition Assay 
 Competition assays were done to test if protein of nonfunctional hybrids was 
being produced. This was done by preparing extracts from hybrids to be tested. Constant 
volumes of the hybrid proteins were spotted along with serial dilutions of the wild type 
colicins (A, E1, and E2) onto lawns of indicator cells. Diminution of the halo size 
indicates the hybrid competes with the wild type colicin. 
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Primers for Amplification of TRAI domains 
Col A-F (TRAI) cgcccggatccaggaaagattatgcctggatttaattatgg 
Col A-R (TRAI) gccgaagcttagcagcatgatcgccagtaaaatgacacaa 
Col E1-F (TRAI) ccagggatccaggattttataatggaaaccgcggtagcgt 
Col E1-R (TRAI) ggtcaagcttccaacaaggaggtttatcgcgaatattcccac 
Col E2-F (TRAI) tataggatccagggaatttttatgagcggtggcg 
Col E2-R (TRAI) ggggaagcttcattcatccataaacaaccggcattcatatttcagccc 
Primers for insertion of XbaI site between R and A domain 
Col A-F ggagataaatataaggcgtctagaatagcgaaagatattgcggac 
Col A-R gtccgcaatatctttcgctattctagacgccttatatttatctcc 
Col E1-F ctccttaattcacagatttctagaaaggatgctgttgatgc 
Col E1-R gcatcaacagcatcctttctagaaatctgtgaattaaggag 
Col E2-F ctgctgcaaaagagaagtcatctagagatgctgatgctgcatt 
Col E2-R aatgcagcatcagcatctctagatgacttctcttttgcagcag 
Primers for Amplification of TR or AI domains 
Col A-F (TR) cgcccggatccaggaaagattatgcctggatttaattatgg 
Col A-R (TR) ccggtctagattccatagcctgacgctgacg 
Col A-F (AI) ctggtctagagttgcggaaaaagccaaagatgagcgggagc 
Col A-R (AI) gccgaagcttagcagcatgatcgccagtaaaatgacacaa 
Col E1-F (TR) ccagggatccaggattttataatggaaaccgcggtagcgt 
Col E1-R (TR) ccgggtctagacttatcagcaagttcctgtgcc 
Col E1-F (AI) ctgggtctagatctaaaggtaagaaaatcggcaatgtgaatgaagctctcgctgc 
Col E1-R (AI) ggtcaagcttccaacaaggaggtttatcgcgaatattcccac 
Col E2-F (TR) tataggatccagggaatttttatgagcggtggcg 
Col E2-R (TR) gcccgctctagactctccttatctaatttatccttagc 
Col E2-F (AI) gatttctagataaacggaataagccagggaaggcgacagg 
Col E2-R (AI) ggggaagcttcattcatccataaacaaccggcattcatatttcagccc 
 
 
 
 
 
 
 
 
 
Table 4. Primers Used to Amplify Colicin Domains. Italicized region indicates the 
restriction sites. 
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3. RESULTS 
 
3.1 Cloning and Mutagenesis of Wild-type Colicins 
 To ensure that the cloned colicin genes would function properly in our vectors, 
the colicin and immunity operon was amplified from each and placed into the pC2G 
vector. This plasmid allows transcription from the tac promoter and carries a copy of the 
lacI gene for regulation. To make these constructs, template DNA was prepared from 
colicin strains A, E1, and E2. BamHI and HindIII restriction sites were inserted by PCR 
as shown in the Figure 7 below. The PCR product was digested with the appropriate 
enzymes and the colicin domains were cloned into the pC2G vector and transformed into 
MB3436 competent cells. The extract produced by each colicin clone strain was tested 
on lawns of wild-type or colicin immune strains. It was observed that the colicin A 
extract lysed pColE1 and pColE2 strains, but a pColA strain remained immune. The 
colicin E1 extract lysed pColA and pColE2 strains, but a pColE1 strain remained 
immune. The colicin E2 extract lysed pColA and pColE1 strains, but a pColE2 strain 
remained immune. Based on these results it was concluded that the expressed extracts 
behaved like the wild-type colicin. Additionally the pC2G clones expressed the 
appropriate immunity function of the cloned colicin. 
An XbaI site was then introduced to create a fusion junction in these constructs 
by site-directed mutagenesis. Clones expressing the Xba mutant protein were tested and 
the results were the same as previously seen by the colicin clones. These results showed 
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that introducing an XbaI site into the colicin gene had no effect and the extract 
maintained the properties of the wild-type colicin. 
 
 
 
 
In addition to testing the colicin activity, the strains were tested to confirm that 
the immunity was maintained as well. Indicator lawns were made with the Xba mutant 
strain and wild-type colicin spotted on the plates. The colicin A Xba mutant remained 
immune to colicin A while being lysed by both colicin E1 and E2. The colicin E1 Xba 
mutant remained immune to colicin E1 but was lysed by both colicin A and E2. The 
colicin E2 Xba mutant remained immune to colicin E2 while being lysed by colicin A 
Figure 7. Schematic Representation of Wild-type Colicin Hybrids. Color represents a 
specific colicin and will be used in the subsequent figures. 
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and E1. Based on these results it was concluded that the Xba mutants maintained their 
immunity as well and were therefore fully functional. 
 In order to test whether the location of the fusion junction affected the behavior 
of the hybrids, an additional Xba mutant was made for colicin E1 and E2. For colicin E1 
the second Xba insertion mutant was eleven residues downstream of the first previously 
described one. For the colicin E2 mutant, one insertion placed downstream the of lepB 
cleavage site and the other was placed upstream of the cleavage site. These Xba mutants 
were also tested and it was seen that there was no difference in the activity of these 
mutants.  
3.2 Construction and Expression of Hybrids 
 Colicin A, E2, and E3 all use the same translocation machinery, whereas colicin 
E1 varies in the proteins used. This causes one to question if there is any specificity in 
the N-terminus of colicins. To see if the translocation machinery used by the colicins 
could be interchanged hybrids were constructed. The hybrids were constructed by 
swapping T-R domains with A-I domains (Figure 8) at the XbaI site. 
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To do this, the DNA from the Xba mutant clones discussed previously was 
digested with XbaI and HindIII, and the A-I domain replaced by an A-I domain from a 
different colicin. The hybrids were transformed into MB3436 and the behavior of the 
colicins was tested after adding IPTG for expression. Because the lysis region is not 
located on these hybrids, sonication was used to release the protein. The resultant lysates 
were then tested against sensitive and various immune strains carrying native colicin 
plasmids.  The results were as follows (Table 5): 
 
 
Figure 8. Schematic Representation of Hybrids. 
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Hybrids Hybrid Activity 
 Wild-type 
(MB3636) 
Col A (MB4017) Col E1 (MB1674) Col E2 (MB1920) 
TRAAIA + - + + 
TRAAIE1 + + - + 
TRAAIE2 - - - - 
TRE1AIA + - + + 
TRE1AIE1 + + - + 
TRE1AIE2 - - - - 
TRE2AIA - - - - 
TRE2AIE1 - - - - 
TRE2AIE2 + + + - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Chart of Hybrid Activity. Protein from the hybrids colicins were spotted onto 
wild-type and immune strains. -: no clearing   +: clearing 
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The hybrid extracts that contained either the T-R or A-I domains from colicin E2 
were all inactive, however the TRE2AIE2 Xba mutant (wild-type hybrid) functioned 
normally. However hybrids between A and E1 pore-forming colicins did function. Based 
on the results it was concluded that the hybrids that contained domains from the 
enzymatic colicin (E2) were not able to function when paired with domains from pore-
forming colicins (A and E1), however hybrids between A and E1, which differ in their 
translocation machinery requirements, were functional. All the hybrids, active or not, did 
express the expected imunity. 
3.3 Stability of Hybrids 
 Serial dilutions of the wild-type, cloned colicins, Xba mutants, and hybrids were 
done to evaluate if the E2 hybrids were nonfunctional due to instability. This was done 
by doing a 10-fold dilution series of all the proteins and placing 5 µL onto LB plates 
seeded with MB3636, which is the pC2G transformed into MB3436. When comparing 
the cloned colicin and the Xba mutants to the wild-type colicins it was seen that that 
stability of the proteins remained the same except for colicin A (Figure 9). A reduction 
in the amount of colicin A lysis activity was observed when cloned into the pC2G 
vector.  Next the hybrids were tested and it was seen that the lysis observed decreased 
approximately 100-fold in all of the hybrids compared to the cloned colicins, and Xba 
mutants (Figure 10). 
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A.         B.                 
C.  
 
Figure 9. Serial Dilutions of Colicins. Dilutions go from left to right and begin with the 
undiluted proteins. (A) from left to right: 10-fold dilutions of wild-type colicins; from top 
to bottom: colicin A, colicin E1, and colicin E2 (B) from left to right: 10-fold dilutions of 
the cloned colicins; from top to bottom: colicin A (4017), colicin E1 (4018), colicin E2 
(4020). (C) from left to right: 10-fold dilutions of the xba mutants; from top to bottom: 
TRAAIA, TRE1-1AIE1-1, TRE1-2AIE1-2, TRE2AIE2 
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3.4 Competition Assay 
 In the previous section the failure of colicin E2 hybrids to have activity was 
described. From this lack of activity it was unclear whether the protein was present but 
nonfunctional or not present at all, presumably due to instability. A competition assay 
was used in an attempt to answer this question. This assay relies on competition between 
the wild-type colicins and the hybrids in binding to a limited number of receptors present 
on the cell surface. These were then tested against the wild type colicins in the ratios 
shown in Table 6. 
 
Figure 10. 10-fold Dilutions of the Hybrid Proteins. The dilutions go from left to right 
and begins with the undiluted protein. (A) from top to bottom: TRE1-1AIE2, TRE1-1AIA, 
TRE1-2AIE2, TRE1-2AIA (B) from top to bottom: TRAAIE1-1, TRAAIE1-2, TRAAIE2 (C) from top 
to bottom: TRE2AIE1-1, TRE2AIE1-2, TRE2AIA 
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1) 10 µl Hybrid + 10µl Col A 
2) 10 µl Hybrid + 10µl 10-1 Col A 
3) 10 µl Hybrid + 10µl 10-2 Col A 
4) 10 µl Hybrid + 10µl 10-3 Col A 
 
5) 10 µl Hybrid + 10µl Col E1 
6) 10 µl Hybrid + 10µl 10-1 Col E1 
7) 10 µl Hybrid + 10µl 10-2 Col E1 
8) 10 µl Hybrid + 10µl 10-3 Col E1 
 
9) 10 µl Hybrid + 10µl 10-1 Col E2 
10) 10 µl Hybrid + 10µl 10-2 Col E2 
11) 10 µl Hybrid + 10µl 10-3 Col E2 
12) 10 µl Hybrid + 10µl 10-4 Col E2 
 
13) 10 µl Hybrid + 10µl pC2G 
14) 10 µl Hybrid + 10µl 10-1 pC2G 
15) 10 µl Hybrid + 10µl 10-2 pC2G 
16) 10 µl Hybrid + 10µl 10-3 pC2G 
 
 
This assay was done by preparing extracts from the colicin E2 hybrids. Next 
dilutions of the wild-type colicins were made as described in Table 6 and 5 µL of each 
dilution was spotted onto lawns of pC2G, pCol A, pCol E1, or pCol E2 strains. The 
dilutions of the wild-type colicins were mixed with one of the four Col E2 hybrids and 
spotted onto the same lawns. An example of the competition assay is shown below 
plated onto a lawn of  the pC2G control strain, If hybrid protein was present one might 
expect a reduction in the signal seen when the hybrid was added to the dilutions of the 
wild type colicins (Figure 11).  
Table 6. Competition Assay Chart.  
 34 
A.            B.  
 
 
These data show an apparent decrease in halo size with the hybrid colicin. To test 
whether the reduction seen in Figure 11 was from the hybrid colicin competition and not 
some other protein in the extract, another control competition assay was set up with the 
wild-type colicins and an extract from MB3636 (Figure 12). To do this dilutions were 
made of the wild-type colicins according to Table 6 and 5 µL of each dilution was added 
onto lawns with either the pC2G, pCol A, pCol E1, or pCol E2 strain. The dilutions of 
the wild-type protein were mixed with MB3636 extract and spotted onto the same lawns. 
Figure 11. Competition Assay Between Wild-Type Colicins and TRE2AIE1. (A) The 
first row is a serial dilution of colicin A. The second row is the same colicin A dilution 
mixed with the hybrid extract. The third row is a serial dilution of colicin E1. The fourth 
row is the same colicin E1 dilution mixed with the hybrid extract. (B) The first row is a 
serial dilution of colicin E2. The second row is the same colicin E2 dilution mixed with 
the hybrid extract. The third row is a serial dilution of MB3636. The fourth row is the 
same MB3636 dilution mixed with the hybrid extract. 
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This assay displayed the same reduction seen previously. Therefore it can be 
concluded that the observed reduction in the halo size was due to some factor in the 
extracts and not the hybrid colicin. Therefore this competition assay was not be a 
suitable test to demonstrate that hybrid protein was present. 
3.5 SDS-PAGE Gel 
 With the failure of the competition assay to show that E2 hybrid protein was 
present, the next step was to try to visualize the protein on an SDS-PAGE gel. To 
prepare samples, overnight cultures of MB3636 (negative control), the XbaI mutants 
(positive control), and the hybrids were grown and induced the next day. Next, 200 µL 
of cells were spun at full speed and resuspended in 100 µL of loading buffer. The 
samples were boiled for 10 minutes and 15 µL was run on a 10 % SDS-PAGE gel. 
Figure 12. Competition Assay Between Wild-Type Colicins and MB3636. (A) The first 
row is a serial dilution of colicin A. The second row is the same colicin A dilution 
mixed with MB3636 extract. The third row is a serial dilution of colicin E1. The fourth 
row is the same colicin E1 dilution mixed with MB3636 extract. (B) The first row is a 
serial dilution of colicin E2. The second row is the same colicin E2 dilution mixed with 
MB3636 extract. The third row is a serial dilution of MB3636. The fourth row is the 
same MB3636 dilution mixed with MB3636 extract. 
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 The wild-type colicin proteins are approximately 60 kDa. If protein is present 
there will be a band around 60 kDa in the samples that is not present in MB3636. Based 
on the gel the only sample that displayed a band was the colicin E2-Xba mutant (Figure 
13). This is possibly due to the colicin E2-Xba mutant being more highly expressed or 
more stable than the other proteins which was shown previously in Figure 9. The protein 
gel was also inconclusive in showing whether protein was present in the nonfunctional 
hybrids probably due to low levels of the protein. A more sensitive method to visualize 
that the level of protein expression by these hybrids would be a western blot. This would 
have been the next step but our lab did not have the appropriate antibodies to run the 
western gels. 
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Figure 13. Protein Extracts on a SDS-PAGE Gel. The circle on the top gel indicates 
the putative colicin E2-Xba mutant protein. 
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4. SUMMARY AND CONCLUSIONS 
 
 
 
 Colicins are the well-studied bacteriocins of the Gram negative bacterium E. coli. 
There is interest in research on enzymatic colicins, especially in understanding the 
differences in their mode of entry compared to pore-forming colicins. The focus of this 
project was to further understand the entry mechanism of enzymatic colicins by 
understanding the phenotype of cim mutants. 
 Cim mutants were previously discovered by finding “tolerant” mutants to 
enzymatic colicins but not pore-forming colicins that were due to a mutation in the tolB 
gene. These mutants were shown to have a single base change that resulted in an amino 
acid change. Although TolB is essential for translocation of colicins A, E2, and E3, cells 
that display the Cim phenotype are only resistant to colicin E2 and E3.    
The first step in this project was to build hybrids by swapping domains between 
pore-forming (A and E1) and enzymatic (E2) colicins. Many hybrids have been 
described previously that exchanged domains between pore-forming colicins or 
attaching segments of other proteins to pore-forming colicins (1, 20). These hybrids 
were able to function properly and gave insight in understanding the entry of pore-
forming colicins. For example, Duche’ generated a hybrid in which a signal peptide was 
attached to the activity domain of colicin A. This hybrid was inactive and the cells grew, 
which showed that pore-forming colicins can only form channels if they enter the inner 
membrane from the periplasmic side as opposed to the cytoplasmic side (14). Other 
hybrids involving enzymatic colicins have been made by exchanging domains between 
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enzymatic colicins or other enzymatic bacteriocins. Kageyama et al. formed a series of 
hybrids by swapping domains between pyocins, enzymatic bacteriocins produced by 
Pseudomonas, and colicins E2 and E3. This was done in an attempt to form a pyocin that 
possesses RNase activity. Like the pore-forming hybrids previously discussed, these 
hybrids were also functional. Although many hybrids have been made in the past, there 
have been no published hybrids prior to my work that include domains from both a pore-
forming and enzymatic colicin. 
My work has shown that hybrids composed of both pore-forming and enzymatic 
colicins (TRAAIE2, TRE1AIE2, TRE2AIA, TRE2AIE1) were nonfunctional, whereas hybrids 
between only pore-forming colicins (TRAAIE1, TRE1AIA) functioned as expected. The 
first set of colicin E2 hybrids I made had the XbaI insertion downstream of the lepB 
cleavage site, this would have caused the cleavage site to be carried along with the 
colicin E2 T-R domains instead of the A-I domains. Because previous research 
mentioned that the activity domain had to be cleaved by LepB in order for the activity 
domain of enzymatic colicins to be functional, another colicin E2 Xba mutant was 
constructed in which the XbaI insertion was placed upstream of the cleavage site. A 
complete set of hybrids were created and tested, these still remained nonfunctional. 
There are a variety of possible explanations that can explain why these hybrids were 
nonfunctional. 
 One reason could be that the immunity protein for enzymatic colicins is carried 
along with the secreted colicin and never released. This is different from pore-forming 
colicins, where the immunity proteins remain in the producing cells. Because pore-
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forming colicins do not need to remove their immunity protein once they enter their 
target cell, they may not have a recognition element needed to remove the immunity 
protein from the hybrid colicin and activate it. If the recognition element needed to 
remove the immunity protein is located in the T-domain this could explain why hybrids 
TRAAIE2 and TRE1AIE2 are nonfunctional.   
 Another possible explanation is that the activity domain may not be cleaved so 
that it can enter the cytoplasm and carry out its lethal activity. It was shown by de 
Zamaroczy that in order for enzymatic colicins to become active, the activity domain 
must be cleaved to allow it to enter the cytoplasm (13). On the other hand, it was seen by 
Masi that when pore-forming colicins are cleaved they are inactivated, which means that 
this is a unique step for enzymatic colicins (28). Since cleavage causes pore-forming 
colicins to become inactive, it would make sense for these colicins to not have the 
machinery or conserved sequence needed for cleavage. This phenomenon may explain 
why the hybrids that contain a pore-forming T-R domain and enzymatic A-I domain 
were inactive. Despite making fusions on either side of the LepB recognition site, there 
may be contextual information in the T or R domain necessary for its recognition and 
cleavage. 
 In addition to the hybrids containing the A-I domain of the enzymatic colicins 
being nonfunctional, the hybrids that contained the T-R domain of the enzymatic 
colicins were also nonfunctional. Due to research done in the past, a logical explanation 
may be that enzymatic colicins contain extra recognition elements in their T-R domain 
that would cause the activity domain of the pore-forming colicins to be cleaved and 
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released into the cytoplasm where they would be nonfunctional. Previous research 
probed whether colicin A could function in the cytoplasm or not (14). This was done by 
deleting the immunity and lysis domains on the colicin A plasmid. This produced a cell 
that accumulated colicin A with no immunity protein to protect the cell. It was observed 
that, although the cell was not protected, it was not lysed by the colicin. If the machinery 
needed for enzymatic colicin cleavage is found in the T or R domain it would cause the 
hybrids that contain the T-R domain from the enzymatic colicin and the A-I domains 
from pore-forming colicins to become inactive, due to the activity domain of the pore-
forming colicin being cleaved. 
 The last plausible explanation for the E2 hybrids being nonfunctional is that the 
hybrid colicins are not as stable as the wild-type and cloned colicins. I attempted to test 
this by performing a serial dilution of the wild-type colicins, the cloned colicins, the Xba 
mutants, and the hybrids. The results indicated that the wild-type, cloned colicins and 
Xba mutants were able to be diluted approximately 100-fold times more than the 
hybrids. 
 Unfortunately because the E2 hybrids were nonfunctional, we were unable to test 
the hybrids against the cim mutants. Despite this setback we were able to learn more 
about the differences between pore-forming and enzymatic colicins. One major 
difference is the need for additional recognition elements by enzymatic colicins, either 
for removal of the immunity protein or cleavage of the activity domain. Another 
difference is the ability of the enzymatic colicins to function in the cytoplasm whereas 
the pore-forming colicins can not. Because of these differences it may be likely that the 
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Cim phenotype is caused because the T domain of enzymatic colicins must interact with 
this region of TolB to remove the immunity protein and therefore expose the LepB 
cleavage site, a step not required with pore-forming colicins. 
Future research could include exchanging the translocation or receptor domain 
between pore-forming and enzymatic colicins instead of exchanging them together. This 
would allow some insight on whether the translocation or the receptor domain processes 
the extra recognition elements needed by enzymatic colicins and it could explain why 
the E2 hybrids designed in my project were nonfunctional. These hybrids could be tested 
against wild-type colicins and the cim mutants to further understand the phenotype of 
these mutants and the import of enzymatic colicins.  
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